Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: Suicide Risk For Users Of Pfizer’s Anti-Smoking Drug Chantix

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency warning echoes changed label; so far, 34 suicides and 420 cases of suicidal thoughts.

You may also be interested in...



Chantix Faces FDA Safety Gauntlet After Pfizer Settles Product Liability Suits

FDA advisory committees will discuss risk of serious neuropsychiatric adverse events with the smoking cessation drug at October meeting.

FDA Suicidality Reassessments Will Be Made At Division Level, Not Through Guidance

Decisions on whether to add drugs or classes of drugs to a list FDA has published of investigational products that need suicidality assessments will be made at the division level, the agency says.

FDA Suicidality Reassessments Will Be Made At Division Level, Not Through Guidance

Decisions on whether to add drugs or classes of drugs to a list FDA has published of investigational products that need suicidality assessments will be made at the division level, the agency says.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel